Bausch Health Companies Inc. (NYSE:BHC) Receives $7.42 Consensus PT from Brokerages

Shares of Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the seven analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $7.42.

Several research analysts have recently weighed in on BHC shares. Royal Bank of Canada cut their price target on Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating for the company in a research note on Thursday, January 30th. Jefferies Financial Group restated a "hold" rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. Finally, StockNews.com upgraded Bausch Health Companies from a "hold" rating to a "buy" rating in a research note on Friday, October 25th.

Bausch Health Companies Price Performance

Shares of Bausch Health Companies stock traded up $0.02 during trading hours on Monday, hitting $6.38. 2,091,841 shares of the company's stock traded hands, compared to its average volume of 3,219,670. Bausch Health Companies has a 12-month low of $3.96 and a 12-month high of $11.46. The stock has a market capitalization of $2.31 billion, a price-to-earnings ratio of -13.28, a PEG ratio of 0.34 and a beta of 0.68. The company has a fifty day simple moving average of $7.52 and a 200-day simple moving average of $7.44.

Hedge Funds Weigh In On Bausch Health Companies

Large investors have recently modified their holdings of the company. Goldentree Asset Management LP increased its stake in Bausch Health Companies by 31.0% in the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company's stock worth $239,552,000 after purchasing an additional 6,958,717 shares during the period. Vanguard Group Inc. increased its stake in Bausch Health Companies by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 11,684,859 shares of the company's stock worth $94,460,000 after purchasing an additional 145,078 shares during the period. Franklin Resources Inc. increased its stake in Bausch Health Companies by 1.1% in the 4th quarter. Franklin Resources Inc. now owns 5,316,822 shares of the company's stock worth $42,855,000 after purchasing an additional 56,446 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in Bausch Health Companies by 46.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company's stock worth $38,501,000 after purchasing an additional 1,510,445 shares during the period. Finally, Bank of Montreal Can increased its stake in Bausch Health Companies by 234.0% in the 3rd quarter. Bank of Montreal Can now owns 3,833,179 shares of the company's stock worth $31,598,000 after purchasing an additional 2,685,675 shares during the period. 78.65% of the stock is owned by hedge funds and other institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.